Cardiology

This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.

Nearly one-third of US adults aged 60 years and older continue to take daily aspirin despite published evidence recommending against use in the absence of CVD.

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

Your daily dose of the clinical news you may have missed.

ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.

ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.

Fiver years after ACS, a new study shows women are less likely to be on lipid lowering therapy and to meet LCL-C target levels than men.

Described as a giant and a pioneer in the hypertension and metabolic fields, Bakris is also remembered so fondly by colleagues as a very special man.

The doubling of the diagnosis of chronic hypertension in pregnancy was accompanied by no increase in treatment rates, according to a new study.

Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

As xylitol is used increasingly to replace sugar in an array of food and other products, Clinic reselinic researchers call for increased scientific scrutiny rchers call for increased scrutiny..

In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.

Your daily dose of the clinical news you may have missed.

ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.

Your daily dose of the clinical news you may have missed.

Plozasiran, in the phase 2b MUIR trial, significantly reduced triglyceride and triglyceride rich lipoprotein levels through targeted action against APOC3.

Findings underscore a need for public health initiatives to educate vulnerable populations on cardiometabolic risks, researchers report.

Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.

Find details on a novel web tool found to help patients determine their eligibility for OTC statin use, FDA clearance of the first AI-based algorithm to detect HF during routine exams, and more.

Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.